SGTX - Eli Lilly closes Sigilon Versanis buyouts boosting diabetes/ obesity franchise
2023-08-14 10:03:16 ET
More on Eli Lilly
- Eli Lilly Remains A Buy With Strong Sales And Possible Upside With Mounjaro
- Inside Eli Lilly's Strategic Investment In Sigilon: An Opportunity Overlooked
- Eli Lilly: There Is No Logic To This Over Optimism
- Eli Lilly: Does 'Miracle' Weight Loss Franchise Justify Rising Price Tag?
- Lilly's Alzheimer's Data For Donanemab
- Eli Lilly upgraded at Jefferies on Mounjaro sales and Wegovy data (update)
For further details see:
Eli Lilly closes Sigilon, Versanis buyouts boosting diabetes/ obesity franchise